A New Medicine for Alzheimer's Disease
Development of EP2 Receptor Antagonist to Treat Alzheimer's Disease
This research looks for a new medicine to slow down or stop Alzheimer's disease progression in people.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11194455 on NIH RePORTER |
What this research studies
Alzheimer's disease is a common cause of memory loss in older adults, and current treatments don't stop its progression. This research explores a new way to fight the disease by targeting a specific pathway in the brain called EP2, which is involved in inflammation. Scientists have created new drug candidates that block EP2 and have seen promising results in lab models, reducing inflammation and amyloid plaques. The goal is to develop these new medicines further, hoping to protect brain function and improve memory for those with Alzheimer's.
Who could benefit from this research
Good fit: This research is ultimately for individuals living with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients without Alzheimer's disease would not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this new medicine could slow or halt the progression of Alzheimer's disease and improve cognitive function.
How similar studies have performed: Early studies in animal models have shown that blocking the EP2 pathway can reduce inflammation and amyloid plaques, and protect brain function.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Ganesh, Thota — Emory University
- Study coordinator: Ganesh, Thota
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.